Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy
Open Access
- 8 April 2005
- Vol. 103 (10), 2030-2034
- https://doi.org/10.1002/cncr.20991
Abstract
BACKGROUND Several studies have recently suggested an association between body mass index (BMI) and disease progression after radical prostatectomy. In the current study, the authors examined this association and that between the reciprocal of BMI (INVBMI, 1/BMI) and progression‐free probability in men treated with radical retropubic prostatectomy (RRP) for clinically localized prostate carcinoma. METHODS The authors retrospectively studied 2210 patients who underwent RRP at Memorial Sloan‐Kettering Cancer Center between September 1986 and May 2003. Clinicopathologic variables analyzed included BMI (kg/m2), preoperative serum prostate‐specific antigen level (ng/mL), clinical T classification, year of surgery, race, biopsy‐derived primary and secondary Gleason grades, and INVBMI, known to better correlate with percent body fat than BMI. Cox regression analysis was used to examine the possible association between BMI or its reciprocal with disease progression after controlling for the effects of common prognostic factors. The areas under the receiver operating curve (AUC) for models with and without INVBMI were calculated RESULTS Of the 2210 patients analyzed, 251 experienced disease progression in a median follow‐up time of 25.9 months (range, 0–143 months). After adjusting for all clinical variables, both BMI (P = 0.071; hazards ratio [HR] = 1.027) and INVBMI (P = 0.041; HR < 0.001) were associated with disease progression. However, the areas under AUC for models with and without INVBMI were similar (range, 0.794–0.798). CONCLUSIONS Although conflicting evidence has been reported regarding the link between obesity and an increased risk of developing prostate carcinoma, as well as an increased risk of developing aggressive disease and prostate carcinoma‐related mortality, the authors found weak associations with disease progression for both BMI and INVBMI. These variables were of negligible prognostic value in men who received surgery. Studies with longer follow‐up, that examine alternative end points, and that follow treatment(s) besides surgery are needed. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Obesity and hormone‐dependent tumors: Cohort and co‐twin control studies based on the Swedish Twin RegistryInternational Journal of Cancer, 2003
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsNew England Journal of Medicine, 2003
- Pretreatment Predictors of Time to Cancer Specific Death After Prostate Specific Antigen FailureJournal of Urology, 2003
- Family history of prostate cancer and obesity in relation to high‐grade disease and extraprostatic extension in young men with prostate cancerThe Prostate, 2003
- A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostateProstate Cancer and Prostatic Diseases, 2001
- Leptin and prostate cancerThe Prostate, 2001
- Relationship of Anterior and Posterior Subcutaneous Abdominal Fat to Insulin Sensitivity in Nondiabetic MenObesity Research, 1997
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994
- Obesity and cancer risk: a danish record-linkage studyEuropean Journal Of Cancer, 1994